Related Experiment Videos
Hypertension therapy: current and future strategies
1Department of Internal Medicine, Hospital de la Cruz Roja, Barcelona, Spain.
Insights
Arterial hypertension is a major cardiovascular risk factor. While treating moderate to severe cases reduces mortality, mild hypertension treatment offers no benefit due to drug side effects, necessitating new drug research.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Arterial hypertension is a primary cardiovascular risk factor and a leading cause of death.
- Effective treatment of moderate to severe hypertension significantly reduces cardiovascular mortality and morbidity.
- Mild hypertension (diastolic blood pressure 90-104 mmHg) treatment benefits are outweighed by drug side effects.
Purpose of the Study:
- To review the current understanding of hypertension treatment benefits and risks.
- To highlight the need for continued research in antihypertensive drug development.
- To emphasize the role of existing drugs like beta-blockers in specific cardiovascular conditions.
Main Methods:
- Literature review of clinical trials and pharmacological studies on hypertension.
- Analysis of risk-benefit profiles for treating different hypertension severity levels.
- Evaluation of the efficacy of antihypertensive agents, including beta-blockers.
Main Results:
- Treatment of moderate to severe hypertension demonstrably lowers cerebrovascular and coronary events.
- No significant benefit observed in treating mild hypertension due to adverse drug effects.
- Beta-blockers show efficacy in reducing ventricular hypertrophy and preventing coronary mortality in secondary prevention.
Conclusions:
- Pharmacological research is crucial for developing novel antihypertensive drugs.
- Further development of established agents like beta-blockers is warranted for specific applications.
- Risk-benefit assessment is critical when considering treatment for mild hypertension.
Abstract:
Arterial hypertension is one of the three major cardiovascular risk factors and the most common chronic disorder to cause death. The treatment of hypertension, especially moderate and severe cases, produces a marked reduction in cerebrovascular and coronary mortality and morbidity. Several trials, however, have shown that there is no benefit to be gained from treating mild hypertension (diastolic blood pressure 90-104 mmHg) because the unwanted side-effects of antihypertensive drugs outweigh their potential advantages. For this reason, it is important to continue pharmacological research to find new antihypertensive drugs and to develop further classical agents, such as the beta-blockers, which reduce ventricular hypertrophy and prevent coronary mortality in secondary prevention regimes.